Parenteral Nutrition Graphic source: .

78
Parenteral Nutrition Graphic source: http://www.rxkinetics.com/tpntutorial/1_4.html

Transcript of Parenteral Nutrition Graphic source: .

Page 1: Parenteral Nutrition Graphic source: .

Parenteral Nutrition

Graphic source: http://www.rxkinetics.com/tpntutorial/1_4.html

Page 2: Parenteral Nutrition Graphic source: .

Parenteral Nutrition (Definition)

Components are in elemental or “pre-digested” form– Protein as amino acids– CHO as dextrose– Fat as lipid emulsion– Electrolytes, vitamins and minerals

Page 3: Parenteral Nutrition Graphic source: .

Parenteral Nutrition (PN) Definition Delivery of nutrients intravenously, e.g. via

the bloodstream.– Central Parenteral Nutrition: often called Total

Parenteral Nutrition (TPN); delivered into a central vein

– Peripheral Parenteral Nutrition (PPN): delivered into a smaller or peripheral vein

A.S.P.E.N. Nutrition Support Practice Manual, 2nd edition, 2005, p. 97

Page 4: Parenteral Nutrition Graphic source: .

Indications for PN (ASPEN) When Specialized Nutrition Support (SNS)

is indicated, EN should generally be used in preference to PN. (B)

When SNS is indicated, PN should be used when the gastrointestinal tract is not functional or cannot be accessed and in patients who cannot be adequately nourished by oral diets or EN. (B)

The anticipated duration of PN should be >7 days

ASPEN Board of Directors. JPEN 26;19SA, 2002.; ASPEN Nutrition Support Practice Manual, 2005, p. 108

Page 5: Parenteral Nutrition Graphic source: .

EN vs PN in Critical Care (EAL) R.1. If the critically ill ICU patient is

hemodynamically stable with a functional GI tract, then EN is recommended over PN.

Patients who received EN experienced less septic morbidity and fewer infectious complications than patients who received PN. Strong, Conditional

ADA Evidence Analysis Library, accessed 8/07

Page 6: Parenteral Nutrition Graphic source: .

EN vs PN in Critical Care (EAL)

In the critically ill patient, EN is associated with significant cost savings when compared to PN. There is insufficient evidence to draw conclusions about the impact of EN or PN on LOS and mortality. Strong, Conditional

ADA Evidence Analysis Library, accessed 8/07

Page 7: Parenteral Nutrition Graphic source: .

Common Indications for PN Patient has failed EN with appropriate tube

placement Severe acute pancreatitis Severe short bowel syndrome Mesenteric ischemia Paralytic ileus Small bowel obstruction GI fistula unless enteral access can be placed

distal to the fistula or where volume of output warrants trial of EN

Adapted from Mirtallo in ASPEN, The Science and Practice of Nutrition Support: A Case-Based Core Curriculum. 2001.

Page 8: Parenteral Nutrition Graphic source: .

Contraindications

Functional and accessible GI tract Patient is taking oral diet Prognosis does not warrant aggressive

nutrition support (terminally ill) Risk exceeds benefit Patient expected to meet needs within 14

days

Page 9: Parenteral Nutrition Graphic source: .

PN Central Access

May be delivered via femoral lines, internal jugular lines, and subclavian vein catheters in the hospital setting

Peripherally inserted central catheters (PICC) are inserted via the cephalic and basilic veins

Central access required for infusions that are toxic to small veins due to medication pH, osmolarity, and volume

Page 10: Parenteral Nutrition Graphic source: .

Venous Sites for Access to the Superior Vena Cava

Page 11: Parenteral Nutrition Graphic source: .
Page 12: Parenteral Nutrition Graphic source: .

PICC Lines (peripherally inserted central catheter) PICC lines may be used in ambulatory

settings or for long term therapy Used for delivery of medication as well as

PN Inserted in the cephalic, basilic, median

basilic, or median cephalic veins and threaded into the superior vena cava

Can remain in place for up to 1 year with proper maintenance and without complications

Page 13: Parenteral Nutrition Graphic source: .

PN: Peripheral Access

PN may be administered via peripheral access when

Therapy is expected to be short term (10-14 days)

Energy and protein needs are moderate Formulation osmolarity is <600-900

mOsm/L Fluid restriction is not necessary

A.S.P.E.N. Nutrition Support Practice Manual, 2005; p. 94

Page 14: Parenteral Nutrition Graphic source: .

Parenteral Nutrition

Macronutrients &

Micronutrients

Page 15: Parenteral Nutrition Graphic source: .

Macronutrients: Carbohydrate

Source: Monohydrous dextrose Properties: Nitrogen sparing

Energy source3.4 Kcal/gHyperosmolar

Recommended intake:2 – 5 mg/kg/min50-65% of total calories

Page 16: Parenteral Nutrition Graphic source: .

Macronutrients: Carbohydrate

Potential Adverse Effects: Increased minute ventilation Increased CO2 production Increased RQ Increased O2 consumption Lipogenesis and liver problems Hyperglycemia

Page 17: Parenteral Nutrition Graphic source: .

Macronutrients: Amino Acids

Source: Crystalline amino acids— standard or specialty

Properties: 4.0 Kcal/gEAA 40–50% NEAA 50-

60%Glutamine / Cysteine

Recommended intake:0.8-2.0 g/kg/day15-20% of total calories

Page 18: Parenteral Nutrition Graphic source: .

Macronutrients: Amino Acids

Potential Adverse Effects:

Increased renal solute load

Azotemia

Page 19: Parenteral Nutrition Graphic source: .

Macronutrients: Amino Acids

Specialized Amino Acid Solutions

Branched chain amino acids (BCAA)

Essential amino acids (EAA) Not shown to improve patient outcome More expensive than standard solutions

Page 20: Parenteral Nutrition Graphic source: .

Macronutrients: Lipid Source: Safflower and/or soybean oil Properties: Long chain triglycerides

Isotonic or hypotonic

Stabilized emulsions 10 Kcals/g

Prevents essential fatty acid deficiency

Recommended intake:

0.5 – 1.5 g/kg/day (not >2 g/kg) 12 – 24 hour infusion rate

Page 21: Parenteral Nutrition Graphic source: .

Macronutrients: Lipids

Requirements 4% to 10% kcals given as lipid meets EFA

requirements; or 2% to 4% kcals given as linoleic acid

Generally 500 mL of 10% fat emulsion given two times weekly or 500 mL of 20% lipids given once weekly will prevent EFAD

Usual range 25% to 35% of total kcals Max. 60% of kcal or 2 g fat/kg

Page 22: Parenteral Nutrition Graphic source: .

Macronutrients: Lipids

Potential Adverse Effects: Egg allergy Hypertriglyceridemia Decreased cell-mediated immunity (limit to

<1 g/kg/day in critically ill immunosuppressed patients)

Abnormal LFTs

Page 23: Parenteral Nutrition Graphic source: .

Parenteral Base SolutionsParenteral Base Solutions Carbohydrate

– Available in concentrations from 5% to 70%– D30, D50 and D70 used for manual mixing

Amino acids– Available in 3, 3.5, 5, 7, 8.5, 10, 15, 20% solutions– 8.5% and 10% generally used for manual mixing

Fat– 10% emulsions = 1.1 kcal/ml– 20% emulsions = 2 kcal/ml– 30% emulsions = 3 kcal/ml (used only in mixing TNA,

not for direct venous delivery)

Carbohydrate– Available in concentrations from 5% to 70%– D30, D50 and D70 used for manual mixing

Amino acids– Available in 3, 3.5, 5, 7, 8.5, 10, 15, 20% solutions– 8.5% and 10% generally used for manual mixing

Fat– 10% emulsions = 1.1 kcal/ml– 20% emulsions = 2 kcal/ml– 30% emulsions = 3 kcal/ml (used only in mixing TNA,

not for direct venous delivery)

The A.S.P.E.N. Nutrition Support Practice Manual, 2nd edition, 2005, p. 97; Barber et al. In ASPEN, The Science and Practice of Nutrition Support: A Case-Based Core Curriculum. 2001.

Page 24: Parenteral Nutrition Graphic source: .

Other RequirementsOther Requirements

Fluid—30 to 50 ml/kg (1.5 to 3 L/day)

– Sterile water is added to PN admixture to meet fluid requirements

Electrolytes– Use acetate or chloride forms to

manage metabolic acidosis or alkalosis Vitamins: multivitamin formulations Trace elements

Fluid—30 to 50 ml/kg (1.5 to 3 L/day)

– Sterile water is added to PN admixture to meet fluid requirements

Electrolytes– Use acetate or chloride forms to

manage metabolic acidosis or alkalosis Vitamins: multivitamin formulations Trace elements

Page 25: Parenteral Nutrition Graphic source: .
Page 26: Parenteral Nutrition Graphic source: .

Electrolytes/Vitamins/Trace Elements Because parenterally-administered vitamins

and trace elements do not go through digestion/absorption, recommendations are lower than DRIs

Salt forms of electrolytes can affect acid-base balance

Page 27: Parenteral Nutrition Graphic source: .

Adult Parenteral Multivitamins

New FDA requirements published in 2000 replacing NAG-AMA guidelines

Increased B1, B6, vitamin C, folic acid, added Vitamin K

MVI Adult (Mayne Pharma) and Infuvite (MVI-13) from Baxter contain Vitamin K and are consistent with the new FDA guidelines

MVI-12 (Mayne Pharma) does not contain Vitamin K

Page 28: Parenteral Nutrition Graphic source: .

Parenteral Nutrition Vitamin Guidelines

Vitamin FDA Guidelines*

A IU 3300 IU

D IU 200 IU

E IU 10 IU

K mcg 150 mcg

C mg 200

Folate mcg 600

Niacin mg 40

Vitamin FDA Guidelines*

B2 mg 3.6

B1 mg 6

B6 mg 6

B12 mg 5.0

Biotin mcg 60

B5 dexpanthenol

mg

15

*Federal Register 66(77): April 20, 2000

Page 29: Parenteral Nutrition Graphic source: .

Daily Trace Element Supplementation for Adult PN

TRACE ELEMENT INTAKE

Chromium 10-15 mcg

Copper 0.3-0.5 mg

Manganese 60-100 mcg

Zinc 2.5-5.0 mg

ASPEN: Safe practices for parenteral nutrition formulations. JPEN 22(2) 49, 1998

Page 30: Parenteral Nutrition Graphic source: .

Daily Electrolyte Requirements Adult PNElectrolyte PN Equiv

RDAStandard Intake

Calcium 10 mEq 10-15 mEq

Magnesium 10 mEq 8-20 mEq

Phosphate 30 mmol 20-40 mmol

Sodium N/A 1-2 mEq/kg + replacement

Potassium N/A 1-2 mEq/kg

Acetate N/A As needed for acid-base

Chloride N/A As needed for acid-base

ASPEN: Safe practices for parenteral nutrition formulations. JPEN 22(2) 49, 1998

Page 31: Parenteral Nutrition Graphic source: .

PN Contaminants

Components of PN formulations have been found to be contaminated with trace elements

Most common contaminants are aluminum and manganese

Aluminum toxicity a problem in pts with renal compromise on long-term PN and in infants and neonates

Can cause osteopenia in long term adult PN patients

ASPEN Nutrition Support Practice Manual 2005; p. 109

Page 32: Parenteral Nutrition Graphic source: .

PN Contaminants

FDA requires disclosure of aluminum content of PN components

Safe intake of aluminum in PN is set at 5 mcg/kg/day

Page 33: Parenteral Nutrition Graphic source: .

PN Contaminants Manganese toxicity has been reported in

long term home PN patients May lead to neurological symptoms Manganese concentrations of 8 to 22

mcg/daily volume have been reported in formulations with no added manganese

May need to switch to single-unit trace elements that don’t include manganese

ASPEN Nutrition Support Practice Manual 2005; p. 98-99

Page 34: Parenteral Nutrition Graphic source: .

Calculating Nutrient NeedsCalculating Nutrient Needs

Provide adequate calories so protein is not used as an energy source

Avoid excess kcal (>35 kcal/kg) Determine energy and protein needs

using usual methods (kcals/kg, Ireton-Jones 1992, Harris-Benedict)

Use specific PN dosing guides for electrolytes, vitamins, and minerals

Provide adequate calories so protein is not used as an energy source

Avoid excess kcal (>35 kcal/kg) Determine energy and protein needs

using usual methods (kcals/kg, Ireton-Jones 1992, Harris-Benedict)

Use specific PN dosing guides for electrolytes, vitamins, and minerals

Page 35: Parenteral Nutrition Graphic source: .

Protein Requirements

1.2 to 1.5 g protein/kg IBW mild or moderate stress

Up to 2.5 g protein/kg IBW burns or severe trauma

Page 36: Parenteral Nutrition Graphic source: .

Peripheral Parenteral Nutrition Hyperosmolar solutions cause

thrombophlebitis in peripheral veins Limited to 800 to 900 mOsm/kg (MHS

uses 1150 mOsm/kg w/ lipid in the solution)

Dextrose limited to 5-10% final concentration and amino acids 3% final concentration

Electrolytes may also be limited Use lipid to protect veins and increase

calories

Page 37: Parenteral Nutrition Graphic source: .

Peripheral Parenteral Nutrition

New catheters allow longer support via this method

In adults, requires large fluid volumes to deliver adequate nutrition support (2.5-3L)

May be appropriate in mild to moderate malnutrition (<2000 kcal required or <14 days)

More commonly used in infants and children Controversial

Page 38: Parenteral Nutrition Graphic source: .

Contraindications to Peripheral Parenteral Nutrition Significant malnutrition Severe metabolic stress Large nutrition or electrolyte needs

(potassium is a strong vascular irritant) Fluid restriction Need for prolonged PN (>2 weeks) Renal or liver compromise

From Mirtallo. In ASPEN, The Science and Practice of Nutrition Support: A Case-Based Core Curriculum. 2001, 222.

Page 39: Parenteral Nutrition Graphic source: .

Compounding Methods

Total nutrient admixture (TNA) or 3-in-1– Dextrose, amino acids, lipid, additives are

mixed together in one container– Lipid is provided as part of the PN mixture on a

daily basis and becomes an important energy substrate

2-in-1 solution of dextrose, amino acids, additives – Typically compounded in 1-liter bags– Lipid is delivered as piggyback daily or

intermittently as a source of EFA

Page 40: Parenteral Nutrition Graphic source: .

Advantages of TNA

Decreased nursing time Decreased risk of touch contamination Decreased pharmacy prep time Cost savings Easier administration in home PN Better fat utilization in slow, continuous

infusion of fat Physiological balance of macronutrients

Page 41: Parenteral Nutrition Graphic source: .

Disadvantages of TNA

Diminished stability and compatibility IVFE (IV fat emulsions) limits the amount

of nutrients that can be compounded Limited visual inspection of TNA; reduced

ability to detect precipitates

ASPEN Nutrition Support Practice Manual 2005; p. 98-99

Page 42: Parenteral Nutrition Graphic source: .

Two-in-One PN

Page 43: Parenteral Nutrition Graphic source: .

PN Compounding Machines: Automix

Page 44: Parenteral Nutrition Graphic source: .

PN Compounding Machines: Micromix

Page 45: Parenteral Nutrition Graphic source: .

PN Solution Componentsa

Central Peripheral

---Solutions--- Solutions

Lipid- Dextrose-

based based

Dextrose 14.5% 35.0% <10.0%

Amino Acids 5.5% 5.0% <4.25%

Fat 5.0% 250 ml/ 3.0 - 8.0%

20% fat q

M,Tha% Final Concentration Courtesy of Marian, MJ.

Page 46: Parenteral Nutrition Graphic source: .
Page 47: Parenteral Nutrition Graphic source: .
Page 48: Parenteral Nutrition Graphic source: .

Initiation of PN

Adults should be hemodynamically stable, able to tolerate the fluid volume necessary to deliver significant support, and have central venous access

If central access is not available, PPN should be considered (more commonly used in neonatal and peds population)

Start slowly(1 L 1st day; 2 L 2nd day)

ASPEN Nutrition Support Practice Manual 2005; p. 98-99

Page 49: Parenteral Nutrition Graphic source: .

Initiation of PN: formulation

As protein associated with few metabolic side effects, maximum amount of protein can be given on the first day, up to 60-70 grams/liter

Maximum CHO given first day 150-200 g/day or a 15-20% final dextrose concentration

In pts with glucose intolerance, 100-150 g dextrose or 10-15% glucose concentration may be given initially

ASPEN Nutrition Support Practice Manual 2005; p. 98-99

Page 50: Parenteral Nutrition Graphic source: .

Initiation of PN: Formulation

Generally energy and protein needs can be met in adults by day 2 or 3

In neonates and peds, time to reach full support relates inversely to age, may be 3-5 days

Page 51: Parenteral Nutrition Graphic source: .

Initiation of PN: Formulation

Dextrose content of PN can be increased if capillary blood glucose levels are consistently <180 mg/dL

IVFE in PN can be increased if triglycerides are <400 mg/dL

ASPEN Nutrition Support Practice Manual 2005; p. 109

Page 52: Parenteral Nutrition Graphic source: .

PN Administration:Transition to Enteral Feedings in Adults Controversial In adults receiving oral or enteral nutrition

sufficient to maintain blood glucose, no need to taper PN

Reduce rate by half every 1 to 2 hrsor switch to 10% dextrose IV) may prevent rebound hypoglycemia (not necessary in PPN)

Monitor blood glucose levels 30-60 minutes after cessation

Page 53: Parenteral Nutrition Graphic source: .

PN Administration:Transition to Enteral Feedings in Pediatrics Generally tapered more slowly than in

adults as oral or enteral feedings are introduced and advanced

Generally PN is continued until 75-80% of energy needs are met enterally

ASPEN Nutrition Support Practice Manual 2005; p. 109

Page 54: Parenteral Nutrition Graphic source: .

Medications That May Be Added to Total Nutrient Admixture (TNA) Phytonadione Selenium Zinc chloride Levocarnitine Insulin

Metoclopromide Ranitidine Sodium iodide Heparin Octreotide

Page 55: Parenteral Nutrition Graphic source: .

Parenteral Nutrition

Infusion Schedules

Page 56: Parenteral Nutrition Graphic source: .

Infusion Schedules

Continuous PN

Non-interrupted infusion of a PN solution over 24 hours via a central or peripheral venous access

Page 57: Parenteral Nutrition Graphic source: .

Continuous PN

Advantages Well tolerated by most patients Requires less manipulation

– decreased nursing time– decreased potential for “touch” contamination

Page 58: Parenteral Nutrition Graphic source: .

Continuous PN

Disadvantages Persistent anabolic state

– altered insulin : glucagon ratios– increased lipid storage by the liver

Reduces mobility in ambulatory patients

Page 59: Parenteral Nutrition Graphic source: .

Infusion Schedules Cyclic PN

– The intermittent administration of PN via a central or peripheral venous access, usually over a period of 12 – 18 hours

– Patients on continuous therapy may be converted to cyclic PN over 24-48 hours

Page 60: Parenteral Nutrition Graphic source: .

Cyclic PN

Advantages– Approximates normal physiology of

intermittent feeding– Maintains:

• Nitrogen balance

• Visceral proteins

– Ideal for ambulatory patients• Allows normal activity

• Improves quality of life

Page 61: Parenteral Nutrition Graphic source: .

Cyclic PN

Disadvantages– Incorporation of N2 into muscle stores may be

suboptimal• Nutrients administered when patient is less active

– Not tolerated by critically ill patients– Requires more nursing manipulation

• Increased potential for touch contamination

• Increased nursing time

Page 62: Parenteral Nutrition Graphic source: .

Parenteral Nutrition

Home TPN

Page 63: Parenteral Nutrition Graphic source: .

Home TPN

Safety and efficacydepend on:– Proper selection of patients– Adequate discharge planning/education– Home monitoring protocols

Page 64: Parenteral Nutrition Graphic source: .

Home TPN

Patient selection– Reasonable life expectancy– Demonstrates motivation, competence,

compliance– Home environment conducive to sterile

technique

Page 65: Parenteral Nutrition Graphic source: .

Home TPN: Discharge Planning

Determination whether patient meets payer criteria for PN; completion of CMN forms

Identification of home care provider and DME supplier

Identification of monitoring team for home Conversion of 24-hour infusion schedule to

cyclic infusion with monitoring of patient response

Page 66: Parenteral Nutrition Graphic source: .

Home TPN

Cost effective– Quicker discharge from hospital

– Improved rehabilitation in the home

– Reduced hospital readmissions

Page 67: Parenteral Nutrition Graphic source: .

Common Indications for PN in Peds Surgical GI disorders Intractable diarrhea of infancy Short bowel syndrome Inflammatory bowel disease Intractable chylothorax Intensive cancer treatment

Page 68: Parenteral Nutrition Graphic source: .

Pediatric Energy Needs in PN

No consensus exists as to how to determine energy needs of hospitalized children

RDAs are intended for healthy children but can use for healthy/acutely ill children and monitor response

Can estimate REE using WHO equation and add stress factors, monitor clinical course

Indirect calorimetry recommended in difficult cases

Page 69: Parenteral Nutrition Graphic source: .

RDAs for Energy and ProteinCategory Age (yr) Energy

(kcal/kg/d)

Protein(g/kg/d)

Infants 0.0-0.5 108 2.2

Children 1-3 102 1.2

4-6 90 1.1

7-10 70 1.0

Females 11-14 47 1.0

15-18 40 0.8

Males 11-14 44 1.0

15-18 45 0.9Recommended Dietary Allowances, 10th ed. 1989. National Academy Press, Washington, DC

Page 70: Parenteral Nutrition Graphic source: .

WHO Equations to predict REE from body weight

Sex/Age Range (years) Equation to Derive REE (kcal/d)

Males 0-3 (60.0 x wt) – 54

Males 3-10 (22.7 x wt) + 495

Males 10-18 (17.5 x wt) + 651

Females 0-3 (6.1 x wt) – 51

Females 3-10 (22.5 x wt) + 499

Females 10-18 (12.2 x wt) + 746

Page 71: Parenteral Nutrition Graphic source: .

Increase WHO REE by stress factorsFever Increase 13% per degree

C

Cardiac Failure 15-25%

Traumatic Injury 20-30%

Severe respiratory distress or broncho-pulmonary dysplasia

25-30%

Severe sepsis 45-50

Olson, D. Pediatric Parenteral Nutrition. In Sharpening your skills as a nutrition support dietitian. DNS, 2003.

Page 72: Parenteral Nutrition Graphic source: .

Trauma/Critically Ill Peds

Age in years Kcals/kg G/pro/kg

0-1 90-120 2.0-3.5

1-6 75-90 1.8-3.0

7-12 50-75 1.5-2.5

13-18 30-60 1.0-2.0

Page 73: Parenteral Nutrition Graphic source: .
Page 74: Parenteral Nutrition Graphic source: .

Pediatric PN: Fluids

Standard calculation: – 100 kcal/kg for infant 3-10 kg– 1000 kcal + 50 kcal/kg for every kg over 10 kg

for a child 10-20 kg– 1500 kcal + 20 kcal/kg for every kg over 20 kg

for a child over 20 kg– 1 mL fluid/kcal/d + adjustments for fever,

diarrhea, stress, etc.

ASPEN BOD Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN 26;26SA, 2001

Page 75: Parenteral Nutrition Graphic source: .

Pediatric PN: Carbohydrate

Carbohydrate should comprise 45-50% of caloric intake in infants and children (C)

For neonates, CHO delivery in PN should begin at 6-8 mg/kg/minute of dextrose and advanced to 10-14 mg/kg/minute. (B)

ASPEN BOD Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN 26;28-29SA, 2001

Page 76: Parenteral Nutrition Graphic source: .

Pediatric PN: Lipid Preterm: start at .5 g/kg/day and increase by .5g/kg

q day

Infants: Start at 1 g/kg and increase by .5 g/kg/day until the maximum or desired dose is reached; need 0.5 to 1 g/kg/day for EFA needs

Maximum is 3 g/kg for <24 months old and 2.5g/kg for 24 months and older

Page 77: Parenteral Nutrition Graphic source: .

Daily Electrolyte and Mineral Requirements for Peds PtsElectrolyte Infants/Children Adolescents

Sodium 2-6 mEq/kg Individualized

Chloride 2-5 mEq/kg Individualized

Potassium 2-3 mEq/kg Individualized

Calcium 1-2.5 mEq/kg 10-20 mEq

Phosphorus 0.5-1 mmol/kg 10-40 mmol

Magnesium 0.3-0.5 mEq/kg 10-30 mEq

National Advisory Group. Safe practices for parenteral nutrition formulations JPEN 1998;22:49-66

Page 78: Parenteral Nutrition Graphic source: .

Document in Chart

Type of feeding formula and tube Method (bolus, drip, pump) Rate and water flush Intake energy and protein Tolerance, complications, and

corrective actions Patient education